After the UK Parliament voted to reject Prime Minister Theresa May’s proposed Brexit deal with just weeks to go before the United Kingdom’s planned withdrawal from the European Union, the pharmaceutical industry has warned that a no-deal Brexit poses “tangible and immediate threats” to patient safety and public health.
After the UK Parliament voted to reject Prime Minister Theresa May’s proposed Brexit deal with just weeks to go before the United Kingdom’s planned withdrawal from the European Union, the pharmaceutical industry has warned that a no-deal Brexit poses “tangible and immediate threats” to patient safety and public health.
That warning came from the European Federation of Pharmaceutical Industries and Associations (EFPIA) in a statement issued after May’s deal was voted down. EFPIA’s director general, Nathalie Moll, said in a statement that “Now is the time for policy makers in the [United Kingdom] and the [European Union] to put politics aside and put measures in place to prevent patients being harmed by the consequences of Brexit. In particular, from disruption to the supply of medicines including from transport delays at the border and where the development, manufacture, packaging, safety testing, and regulation of the medicine no longer benefits from mutual recognition.”
EFPIA called on negotiators to agree to a set of key actions to protect patients, such as exempting medicines and clinical trial materials from customs and border checks, coordinating fast-track lanes for the transport of medicines into ports, and potentially exempting active pharmaceutical ingredients from border checks to ensure that drug manufacturing can continue with limited disruption.
The Association of the British Pharmaceutical Industry (ABPI) also called on the UK government to bring clarity to the industry. In a statement, Mike Thompson, chief executive of ABPI, said, “We reiterate that ‘no deal’ would prove to be extremely challenging. With time running out, we hope Parliament will come together and quickly find a solution to the stalemate and reassure patients that medicines will not be disrupted come March 2019.”
Meanwhile, drug companies are making their own plans to avoid disruptions to the flow of medicines in the event of a no-deal Brexit. This week, Bloomberg reported that Novo Nordisk has begun to book air freight slots for its medicines so that insulin can be flown into the United Kingdom (which does not manufacture any of its own analogue or synthetic human insulin) if necessary. Fellow insulin maker Sanofi is currently testing alternative routes (from the Netherlands to the eastern coast and from France to the south) into the United Kingdom.
Even before embracing such options, drug makers had begun to stockpile their products after UK Health Secretary Matt Hancock advised that trade delays at the border could last for as long as 6 months. The specific drugs that are being stockpiled are not known, however; as The Guardian reported in December 2018, the UK government has demanded that pharmaceutical companies and organizations that are working in concert with the government to maintain supplies of their products sign nondisclosure agreements that prevent them from disclosing any details of their contingency plans.
Budget Impact Analysis of Biosimilar Natalizumab in the US
Projected savings from biosimilar natalizumab were $452,611 over 3 years, driven by decreased drug acquisition costs and a utilization shift from reference to biosimilar natalizumab.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
BioRationality: Time to Get Rid of PBMs if Biosimilars Are to Succeed
July 15th 2024Sarfaraz K. Niazi, PhD, discusses the challenges with pharmacy benefit managers (PBMs) that plague the biosimilar industry and new legislation that attempts to reform their practices and encourage biosimilar adoption.